Tirzepatide regulatory status

What is the current status of Tirzepatide?

How has the status of Tirzepatide changed over time?

1. Sep 18, 2026FDA

   FDA warning letter treats GLP-1 plus vitamin combinations as essentially copies

   In a warning letter dated September 18, 2026 and posted September 22, FDA said compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin (vitamin B12) appeared to be essentially copies of approved drugs, that the volume produced suggested the claimed differences were a pretext, and that significant-difference statements were repeated verbatim across many records or chosen from preset menus on prescribing platforms. The letter's findings are specific to one pharmacy, but they apply FDA's April 1, 2026 policy that a combination within 10% of approved strengths by the same route may be treated as essentially a copy without a documented prescriber determination.

   Source: FDA warning letter to a compounding pharmacy on semaglutide and tirzepatide vitamin combinations (September 18, 2026)
2. Aug 28, 2026FDA

   FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes

   FDA added an indication for Mounjaro to lower the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events. The approval rests on SURPASS-CVOT, in which tirzepatide was non-inferior to dulaglutide (hazard ratio 0.92, 95.3% CI 0.83 to 1.01) but did not show superiority.

   Regulatory: FDA approvedSource: Manufacturer press release: FDA approves Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes (August 28, 2026)
3. Apr 30, 2026FDA

   FDA proposes to keep semaglutide, tirzepatide and liraglutide off the 503B bulks list

   FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, after tentatively finding no clinical need for outsourcing facilities to compound them from bulk. The notice was published May 1, 2026, and the comment period was extended to July 30, 2026. The proposal was not final as of September 2026. It does not change the 503A rules for patient specific compounding.

   Source: Federal Register 2026-08552: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
4. Mar 19, 2025FDA

   503B grace period for compounded tirzepatide ends

   FDA's enforcement discretion for 503B outsourcing facilities compounding tirzepatide ended, closing the shortage-based pathway for compounded tirzepatide.

   Source: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (Wayback Machine capture of the FDA page, March 13, 2026)
5. Feb 18, 2025FDA

   503A grace period for compounded tirzepatide ends

   FDA's enforcement discretion for 503A pharmacies compounding tirzepatide ended. After this date 503A pharmacies may not compound copies of Mounjaro or Zepbound on shortage grounds.

   Source: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (Wayback Machine capture of the FDA page, March 13, 2026)
6. Dec 20, 2024FDA

   FDA approves Zepbound for obstructive sleep apnea in adults with obesity

   FDA approved Zepbound (tirzepatide) for moderate to severe obstructive sleep apnea in adults with obesity, the first drug approved for that indication.

   Regulatory: FDA approvedSource: FDA approves first medication for obstructive sleep apnea
7. Dec 19, 2024FDA

   FDA reaffirms the tirzepatide shortage is resolved and sets grace periods

   After reconsideration, FDA confirmed the tirzepatide shortage was resolved and announced enforcement discretion periods: 503A pharmacies until February 18, 2025 and 503B outsourcing facilities until March 19, 2025.

   Source: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (Wayback Machine capture of the FDA page, March 13, 2026)
8. Oct 11, 2024Other

   FDA agrees to reconsider the tirzepatide shortage decision after compounder lawsuit

   After the Outsourcing Facilities Association sued over the October 2 resolution decision, FDA told the court it would reconsider the tirzepatide shortage determination and would not take enforcement action against compounders in the interim.

   Source: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (Wayback Machine capture of the FDA page, March 13, 2026)
9. Oct 2, 2024FDA

   FDA declares the tirzepatide shortage resolved

   FDA announced that the shortage of tirzepatide injection (Mounjaro and Zepbound) was resolved, meaning compounders could no longer rely on the shortage to prepare copies of the approved products.

   Source: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (Wayback Machine capture of the FDA page, March 13, 2026)
10. Nov 8, 2023FDA

    FDA approves Zepbound (tirzepatide) for chronic weight management

    FDA approved tirzepatide injection (Zepbound) for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

    Regulatory: FDA approvedSource: FDA approves new medication for chronic weight management
11. Dec 2022FDA

    FDA lists tirzepatide injection on the drug shortage list

    In December 2022 FDA added tirzepatide injection (Mounjaro) to its drug shortage list, opening the door to compounded tirzepatide under FDA's shortage compounding policies.

    Source: FDA drug shortages database
12. May 13, 2022FDA

    FDA approves Mounjaro (tirzepatide) for type 2 diabetes

    FDA approved tirzepatide injection (Mounjaro), the first dual GIP and GLP-1 receptor agonist, to improve glycemic control in adults with type 2 diabetes.

    Regulatory: FDA approvedSource: Drugs@FDA: Mounjaro (tirzepatide) NDA 215866

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Tirzepatide and the source of each dated event.

From the blog

• Compounded tirzepatide in 2026: legality, cost, and safety

  The tirzepatide shortage ended in December 2024 and routine compounded copies ended in 2025. What is still lawful, what it cost, FDA safety warnings, and how to check a pharmacy.

• Microdosing GLP-1s and tirzepatide: what the evidence says

  No trial has tested microdosing semaglutide or tirzepatide. What the labels say about dose steps and why they exist, FDA's dosing-error warnings, and what to ask a prescriber.

• What happened to compounded semaglutide

  Compounded semaglutide went from a shortage workaround to a narrow, patient-specific exception. Here is the timeline, what FDA found, and what access looks like in 2026.